PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 (CAN-004) for Mitigation of Cannabis Withdrawal Symptoms in Patients with Cannabis Use Disorder
Phase 3 trial initiation advances PP-01, an investigational, once-daily therapy for cannabis withdrawal symptoms in patients with cannabis use disorder Cannabis use disorder affects an estimated 20.6 million people in the U.S., underscoring the scale of this unmet medical need...
Phase 3 trial initiation advances PP-01, an investigational, once-daily therapy for cannabis withdrawal symptoms in patients with cannabis use disorder Cannabis use disorder affects an estimated 20.6 million people in the U.S., underscoring the scale of this unmet medical need...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.